Develops and markets health insurance products for seniors and middle-income individuals. Now — the numbers.
This is an established company with proven profits.
No real growth (2% a year).
The market pays 22.4× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 71% of them.
Analysts' average target sits 5% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
For a bank, strength is measured by capital buffers and reserves — not cash minus debt.
Clearly above the class average — a step short of the very top.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
It pays out $0.69 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
On our five-subject report card, CNO sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: CNO is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.